2-[1-(benzenesulphonyl)-1H-indol-4-yl]ethylamine | 297751-22-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[1-(benzenesulphonyl)-1H-indol-4-yl]ethylamine
• 英文别名: 2-[1-(phenylsulfonyl)-1H-indol-4-yl]ethanamine；2-(1-Benzenesulfonyl-1H-indol-4-yl)-ethylamine；2-[1-(benzenesulfonyl)indol-4-yl]ethanamine
• CAS: 297751-22-5
• 化学式: C₁₆H₁₆N₂O₂S
• 分子量: 300.381
• InChiKey: VNWSJGQXBGKBED-UHFFFAOYSA-N

物化性质

• 沸点：
  517.4±42.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  73.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[1-(benzenesulphonyl)-1H-indol-4-yl]ethylamine 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 20.17h， 生成 4-ethyl-1-(phenylsulfonyl)-3,4,5,6-tetrahydro-1H-azepino[3,4,5-cd]indole hydrochloride
  参考文献：
  名称：

  WO2008/110598

  摘要：

  公开号：
• 作为产物：
  描述：

  4-吲哚甲醛 在 nickel boride sodium tetrahydroborate 、 ammonium acetate 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.63h， 生成 2-[1-(benzenesulphonyl)-1H-indol-4-yl]ethylamine
  参考文献：
  名称：

  WO2008/110598

  摘要：

  公开号：

文献信息

• Use
  申请人：——

  公开号：US20030139424A1

  公开（公告）日：2003-07-24

  The invention provides a method of treatment or prophylaxis of obesity or for the reduction of food intake, comprising administering to a patient in need of such treatment a therapeutically effective amount of an indole or indoline derivative of Formula I, II or III: 1 wherein the substituents are as described in the specification.

  本发明提供了一种治疗或预防肥胖或减少食物摄入的方法，包括向需要此类治疗的患者给予公式I、II或III的吲哚或吲哚啉衍生物的治疗有效量：1其中取代基如说明书所述。
• New compounds
  申请人：Angbrant Johan

  公开号：US20080293694A1

  公开（公告）日：2008-11-27

  The present invention relates to novel compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT 6 receptor-related disorders.

  本发明涉及一种新型化合物，其化学式为(I)：其中R1、R2、R3、R4和R5如本文所述，以及包含该化合物的制药组合物，其制备过程以及利用该化合物制备用于治疗5-HT6受体相关疾病的药物的使用。
• <i>N</i>-Arylsulfonylindole Derivatives as Serotonin 5-HT₆ Receptor Ligands
  作者：Michael G. N. Russell、Robert J. Baker、Laura Barden、Margaret S. Beer、Linda Bristow、Howard B. Broughton、Michael Knowles、George McAllister、Smita Patel、José L. Castro

  DOI：10.1021/jm010943m

  日期：2001.11.1

  A series of N-1-arylsulfonyltryptamines were found to be potent ligands of the human serotonin 5-HT6 receptor with the 5-methoxy-1-benzenesulfonyl analogue (19) having the highest affinity. Additionally, it was discovered that a group such as 3-(3-methoxybenzyl)-1,2,4-oxadiazol-5-yI in the 2-position of the indole ring (43) can replace the arylsulfonyl substituent in the 1-position with no loss of affinity. This suggested that the binding conformation of the aminoethyl side chain at this receptor was toward the 4-position of the indole ring and was supported by the fact that the 4-(aminoethyl)indoles (45) also displayed high affinity, as did the conformationally rigid 1,3,4,5-tetrahydrobenz[c,d]indole (49). Molecular modeling showed that 19, 43, and 45 all had low-energy conformers that overlaid well onto 49. Both 19 and 49 had good selectivity over other serotonin receptors tested, with 49 also showing excellent selectivity over all dopamine receptors. In a functional adenylate cyclase stimulation assay, 19 and 49 had no agonist activity, whereas 45 behaved as a partial agonist. Finally, it was shown that 19 had good activity in the 5-HT2A centrally mediated mescaline-induced head twitch assay, which implies that it is brain-penetrant.
• TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY
  申请人：Biovitrum AB (publ)

  公开号：EP2134714A1

  公开（公告）日：2009-12-23
• US6187805B1
  申请人：——

  公开号：US6187805B1

  公开（公告）日：2001-02-13